Beate Charlotte Kvist

• Gaustad, Jon-Vidar; Kvist, Beate Charlotte; Espeland, Anna Lien; Klem, Hanna Eikås & Næss, Gunn Eva (2023). Oncotype DX breast cancer recurrence score test: A single technology assessment. Folkehelseinstituttet. Område for helsetjenester. ISSN 978-82-8406-407-9. Full text in Research Archive
• Ohm, Ingrid Kristine; Kvist, Beate Charlotte; Lidal, Ingeborg Beate; Gulliksrud, Kristine; Stoinska-Schneider, Anna Karina & Næss, Gunn Eva [Show all 8 contributors for this article] (2023). 177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment. Folkehelseinstituttet. ISSN 9788284063829 . Full text in Research Archive Show summary

  177Lu-PSMA-617 is a new radioligand therapy that is being used in treating metastatic castration resistant prostate cancer. It consists of the radionuclide lutetium-177 labelled with the ligand PSMA-617 for specific binding to prostate-specific membrane antigen (PSMA) typically expressed by prostate cancer cells. In this health technology assessment, we included three randomised controlled trials that compared the effect of 177LuPSMA-617, either alone or in combination with standard of care therapy (SoC), to docetaxel, cabazitaxel, or SoC alone. The main efficacy outcome was survival, i.e., overall survival (OS), as well as progression-free survival (PFS). Safety outcome was severe adverse events ≥grade 3 (SAE). The results are presented as hazard ratio (HR) and risk ratio (RR), with an assessment of our conficence in the results (GRADE). 177Lu-PSMA-617 + SoC versus SoC alone (total n=831) - OS: HR 0.62 (0.52 to 0.74) (GRADE: high) - PFS: HR 0.40 (0.31 to 0.51) (GRADE: high) - SAE: RR 1.39 (1.14 to 1.69) (GRADE: moderate) 177Lu-PSMA-617 versus cabazitaxel (total n=200) - PFS: HR 0.63 (0.46 to 0.86) (GRADE: low) - SAE: RR 0.73 (0.18 to 1.04) (GRADE: very low) 177Lu-PSMA-617 versus docetaxel (total n=40) - PFS: HR 0.90 (0.46 to 1.77) (GRADE: very low) - SAE: RR 0.60 (0.27 to 1.34) (GRADE: very low) Treatment with 177Lu-PSMA-617 plus SoC therapy prolonged overall and progression-free survival with median four and five months, respectively, compared with SoC alone, but increased the risk of severe adverse events ≥grade 3 in patients previously treated with hormone therapy and taxane-based chemotherapy. We have high and moderate confidence in these results. 177LuPSMA-617 prolonged progression-free survival and reduced the risk of severe adverse events ≥3 more than cabazitaxel in patients previously treated with docetaxel. However, we have low and very low confidence in these results. There is seemingly no difference in progression-free survival when comparing 177Lu-PSMA-617 with docetaxel in patients who were treatment-naïve, but 177LuPSMA-617 reduced the risk of severe adverse events ≥3 more than docetaxel. However, we have very low confidence in these results. The most common adverse events associated with 177Lu-PSMA617 were fatigue, dry eyes and mouth, and pain. The incidence of more serious adverse events such as nephrotoxicity, was low. Patients’ expectation towards 177Lu-PSMA-617 is first and foremost as a new option for life prolonging treatment for mCRPC. An implementation of 177Lu-PSMA-617 in Norway will likely affect the current organisation and allocation of resources. Furthermore, implementation must ensure that the treatment is managed in line with the Norwegian radiation protection legislation. Our cost-effectiveness analysis shows that treatment with 177LuPSMA-617 together with SoC is more effective, but also more costly than SoC alone in mCRPC patients who previously have been treated with anti-androgen therapy and taxane-based chemotherapy. The incremental cost-effectiveness ratio (ICER) was NOK XX XXXXX per quality adjusted life year (QALY). The absolute shortfall for patients with mCRPC is equal to 11.67 QALYs.

• Hagen, Gunhild; Smedslund, Geir; Denison, Eva Marie-Louise; Kvist, Beate Charlotte Fagerlund & Næss, Gunn Eva (2021). Bronchial thermoplasty for the treatment of severe ashma: A single technology assessment. Norwegian Institute of Public Health, Division for Health Services. ISSN 978-82-8406-228-0. Full text in Research Archive Show summary

  Key messages: Asthma is a chronic inflammatory illness affecting the airways. Severe asthma is defined as “asthma that is uncontrolled despite maximal optimised therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased”. Patients suffering from severe treatment-resistant asthma currently have few available treatment options, for these patients, bronchial thermoplasty (BT) may be an alternative. BT is a device-based treatment option that uses temperature-controlled radio frequency energy to reduce the amount of airway smooth muscle within the airway wall. Overall, the current evidence base for bronchial thermoplasty indicates no clear and well documented positive health effect on the most important outcomes. This single-technology assessment shows that: • The effect of BT on mortality is uncertain • The risk of hospitalization increased during the BT treatment (first 12 weeks). • There was no difference in hospital admissions between BT and sham/control after 12 months. The clinical effectiveness data doesn’t demonstrate a clear difference between BT and control on the rate of exacerbations, hospitalisations, or visits to general practitioner or emergency room. As the central drivers of the suggested health economic model were thus found to be insufficiently documented, the submitted model was not further assessed. Absolute shortfall and severity are not estimated as cost effectiveness is not documented in a cost per QALY analysis. It is estimated that 1258 Norwegian patients with severe asthma may be eligible for bronchial thermoplasty each year. According to the manufacturer, the budget impact when treating 1258 patients with BTwould require about 100 million NOK during the first year.

• Kvist, Beate Charlotte Fagerlund; Holte, Hilde H; Movik, Espen; Bjerk, Maria & Næss, Gunn Eva (2021). Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedemac. Folkehelseinstituttet. ISSN 978-82-8406-188-7. Full text in Research Archive
• Lund, Ulrikke Højslev; Bidonde, Julia; Kornør, Hege; Reinar, Liv Merete Brynildsen; Kvist, Beate Charlotte Fagerlund & Nguyen, Lien [Show all 9 contributors for this article] (2021). Minimally Invasive Glaucoma Surgery (MIGS) for individuals with glaucoma. A health technology assessment . Norwegian Institute of Public Health, Division for Health Services. ISSN 978-82-8406-144-3. Full text in Research Archive Show summary

  Key messages: This health technology assessment (HTA) summarises and supplements a 2019 Canadian HTA on the effectiveness and safety of micro-invasive glaucoma surgery (MIGS) versus other treatment options. Further, it contains cost-effectiveness analysis based on the Canadian HTA, in addition to patient partners’ considerations, organizational and ethical considerations relevant to discussions of MIGS’ role in Norwegian routine care. The Canadian evidence, which included 32 studies and 24 comparisons, was inconclusive due to very low to low certainty. Our supplementary findings show that: • MIGS with Hydrus Microstent combined with cataract surgery reduces intraocular pressure (IOP) at 24 months, compared with cataract surgery alone (high-certainty evidence) • MIGS with iStent inject combined with cataract surgery probably reduces IOP at 24 months, compared with cataract surgery alone (moderate-certainty evidence) • For other techniques there is either no or little difference between the MIGS and control interventions, or it is uncertain whether there is a difference in effectiveness • Neither MIGS procedures, nor alternative surgical strategies appear to be at high risk of adverse events • Lifetime total cost for glaucoma treatment ranged from NOK 30 000 to NOK 83 000 per patient, depending on treatment strategy and baseline disease stage. The incremental Quality adjusted life years (QALYs) for MIGS between comparators ranged between – 0.080 and 0.057 • MIGS is suitable as a outpatient surgery without hospital admission. Clinicians need training. Clear criteria for patient selection shuld be developed. Experts predict that the number of MIGS procedures may increase to twice as many in 2024 than today • The clinical evidence on MIGS is limited. The main reason for this is the lack of comparative studies. Our health economic evaluation shows some scenarios where MIGS may be cost-effective, depending on comparator and disease stage. Our analysis puts individuals with glaucoma in severity class 1.

• Himmels, Jan Peter William; Flottorp, Signe Agnes; Stoinska-Schneider, Anna Karina; Kvist, Beate Charlotte Fagerlund & Robberstad, Bjarne (2021). Transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and low surgical risk and across surgical risk groups: a health technology assessment . Folkehelseinstituttet. ISSN 978-82-8406-160-3. Full text in Research Archive
• Kvist, Beate Charlotte Fagerlund; Chudasama, Kishan Kumar; Brurberg, Kjetil Gundro; Robberstad, Bjarne; Rose, Christopher James & Juvet, Lene Kristine [Show all 7 contributors for this article] (2019). Prosigna genprofiltest for å vurdere forventet nytte av kjemoterapi ved brystkreft. Vurdering av innsendt informasjon. Folkehelseinstituttet. ISSN 978-82-8406-020-0. Full text in Research Archive
• Fagerlund, Beate Charlotte; Stoinska-Schneider, Anna; Lauvrak, Vigdis; Juvet, Lene Kristine & Robberstad, Bjarne (2019). Health technology assessment of Transcatether aortic valve implantation (TAVI) as treatment of patients with severe aortic stenosis and intermediate surgical risk – Part 2. Health economic evaluation. Folkehelseinstituttet. ISSN 978-82-8406-015-6. Full text in Research Archive
• Fagerlund, Beate Charlotte; Lund, Ulrikke Højslev; Harboe, Ingrid & Melien, Øyvind (2018). EXOGEN™ in the treatment of nonunion fractures. A single technology assessment . Folkehelseinstituttet. ISSN 978-82-8082-956-6. Full text in Research Archive
• Fagerlund, Beate Charlotte; Tjelle, Torunn Elisabeth; Harboe, Ingrid; Giske, Liv; Movik, Espen & Elvsaas, Ida-Kristin Ørjasæter [Show all 7 contributors for this article] (2018). MicraTM Transcatheter Pacing system, en pacemaker uten ledning, til pasienter som behøver en enkel‐ventrikkel pacemaker: En hurtigmetodevurdering. Norwegian Institute of Public Health. ISSN 978‐82‐8082‐924‐5. Full text in Research Archive
• Pike, Eva Flovild; Fagerlund, Beate Charlotte; Giske, Liv; Desser, Arna S. & Harboe, Ingrid (2017). Barorefleksstimulator ved behandlingsresistent høyt blodtrykk. Hurtigmetodevurdering. Norwegian Institute of Public Health. ISSN 9788280828217. Full text in Research Archive
• Movik, Espen; Fagerlund, Beate Charlotte; Friberg, Eva Godske; Lund Håheim, Lise & Skår, Åse (2017). Digital Brysttomosyntese med Hologic 3D mammograf Selenia Dimensions System i screening for brystkreft. Hurtigmetodevurdering . Folkehelseinstituttet. ISSN 978-82-8082-873-6. Full text in Research Archive
• Bidonde Torre, Maria Julia; Fagerlund, Beate Charlotte; Frønsdal, Katrine Bjørnebek; Lund, Ulrikke Højslev & Robberstad, Bjarne (2017). FreeStyle Libre-systemet for egenmåling av blodsukker: en hurtigmetodevurdering. Folkehelseinstituttet. ISSN 978‐82‐8082‐852‐1. Full text in Research Archive
• Desser, Arna S.; Arentz-Hansen, Helene; Fagerlund, Beate Charlotte; Harboe, Ingrid & Lauvrak, Vigdis (2017). Suturløse implanterbare hjerteklaffer i behandling av aortastenose: Hurtigmetodevurdering av Perceval suturløse hjerteklaffer. Folkehelseinstituttet. ISSN 978-82-8082-871-2. Full text in Research Archive
• Pike, Eva; Fagerlund, Beate Charlotte; Giske, Liv; Desser, Arna S. & Harboe, Ingrid (2017). Barorefleksstimulator ved behandlingsresistent høyt blodtrykk. Hurtigmetodevurdering. Folkehelseinstituttet. ISSN 978-82-8082-821-7. Full text in Research Archive
• Pike, Eva Flovild; Bjerkan, Anne Mette; Kvist, Beate Charlotte Fagerlund; Hamidi Ashtiani, Vida; Harboe, Ingrid & Klemp, Marianne (2016). Continuous monitoring of pulmonary artery pressure via an implanted leadless and battery less pressure sensor for the management of patients with moderate to severe heart failure (New York Heart Association class III). A single technology assessment . Norwegian Institute of Public Health / Folkehelseinstitutttet. ISSN 978-82-8082-771-5. Full text in Research Archive

View all works in Cristin